Nerve Conduction Studies of Dorsal Sural Nerve: Normative Data and Its Potential Application in ATTRv Pre-Symptomatic Subjects.
ATTRv
dorsal sural nerve
monitoring
pre-symptomatic carrier
Journal
Brain sciences
ISSN: 2076-3425
Titre abrégé: Brain Sci
Pays: Switzerland
ID NLM: 101598646
Informations de publication
Date de publication:
04 Aug 2022
04 Aug 2022
Historique:
received:
13
07
2022
revised:
28
07
2022
accepted:
01
08
2022
entrez:
26
8
2022
pubmed:
27
8
2022
medline:
27
8
2022
Statut:
epublish
Résumé
The objective of the study is to provide age-related normative values for dorsal sural nerve (DSN) and to analyse its application during follow-up of hereditary transthyretin amyloidosis (ATTRv) pre-symptomatic subjects. We consecutively recruited ATTRv pre-symptomatic carriers in which clinical examination, cardiological evaluation, and nerve conduction studies of the sural nerve and DSN were performed. To provide normative data of DSN, neurophysiologic parameters from healthy controls referred to our service were entered into linear regression analyses to check the relative influence of age and height. A correction grid was then derived. We collected 231 healthy subjects: the mean DSN sensory nerve action potential (SNAP) amplitude was 9.99 ± 5.48 μV; the mean conduction velocity was 49.01 ± 5.31 m/s. Significant correlations were found between age and height with DSN SNAP amplitude. Fifteen ATTRv pre-symptomatic carriers were examined. Sural nerve NCS were normal in 12/15 and revealed low/borderline values in three subjects. Considering our correction grid, we found an abnormal DNS amplitude in 9/15 subjects and low/borderline values in 2/15. In ATTRv, early detection of peripheral nerve damage is crucial to start a disease-modifying treatment. DSN may be easily and reliably included in the routine neurophysiological follow-up of ATTRv pre-symptomatic subjects.
Identifiants
pubmed: 36009100
pii: brainsci12081037
doi: 10.3390/brainsci12081037
pmc: PMC9406159
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Pfizer (Italy)
ID : Investigator-Initiated Research to "Fondazione Policlinico Universitario Agostino Gemelli IRCCS" from Pfizer Inc.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Neurol Sci. 2022 Feb;43(2):1359-1364
pubmed: 34189665
Brain Sci. 2020 Oct 26;10(11):
pubmed: 33114611
Genes (Basel). 2021 Nov 11;12(11):
pubmed: 34828392
Amyloid. 2018 Dec;25(4):242-246
pubmed: 30638075
N Engl J Med. 2018 Jul 05;379(1):22-31
pubmed: 29972757
Amyloid. 2019 Mar;26(1):3-9
pubmed: 30793974
N Engl J Med. 2018 Jul 5;379(1):11-21
pubmed: 29972753
Neurology. 2012 Aug 21;79(8):785-92
pubmed: 22843282
Neurol Sci. 2022 Apr;43(4):2845-2848
pubmed: 35094171
J Neurol. 2021 Jan;268(1):189-198
pubmed: 32749600
Brain Sci. 2021 Jul 24;11(8):
pubmed: 34439599
Nat Rev Neurol. 2019 Jul;15(7):387-404
pubmed: 31209302
Clin Neurophysiol. 2012 Sep;123(9):1891-2
pubmed: 22445278
Muscle Nerve. 2001 Jun;24(6):817-20
pubmed: 11360266
Lancet Neurol. 2011 Dec;10(12):1086-97
pubmed: 22094129
Curr Opin Neurol. 2016 Feb;29 Suppl 1:S14-26
pubmed: 26734952
Eur J Neurol. 2022 Mar;29(3):826-832
pubmed: 34751997
Eur J Neurol. 2022 Jul;29(7):2148-2155
pubmed: 35289020
J Gastrointestin Liver Dis. 2020 Sep 09;29(3):339-343
pubmed: 32919418
Muscle Nerve. 2012 Dec;46(6):895-8
pubmed: 23042443
Ther Clin Risk Manag. 2020 Feb 21;16:109-123
pubmed: 32110029
Genes (Basel). 2021 Jun 22;12(7):
pubmed: 34206500
N Engl J Med. 2018 Sep 13;379(11):1007-1016
pubmed: 30145929